Get started
Author

Elena Álvarez‐Barón

Observed names: Alvarez-Baron, Elena, E Álvarez-Baron, E. Alvarez-Baron, Elena Alvarez-Baron, Elena Alvarez-Barón, Elena Alvarez‐Baron, Elena Alvaréz-Baron, Elena Alvárez‐Barón, Elena Álvarez-Barón
ORCID: 0009-0009-1288-5743
Observed ORCID: 0009-0009-1288-5743
OpenAlex ID: A5066277838
The burden of epilepsy and unmet need in people with focal seizures
2022 · Persefoni Ioannou, Daniella L. Foster, et al. · Brain and Behavior · 187
RIM proteins and their role in synapse function
2010 · Tobias Mittelstaedt, Elena Alvaréz-Baron, et al. · Biological Chemistry · 82
Differential mRNA expression patterns of the synaptotagmin gene family in the rodent brain
2008 · Tobias Mittelsteadt, Gerald Seifert, et al. · The Journal of Comparative Neurology · 82
Autoantibodies to Munc18, cerebral plasma cells and B-lymphocytes in Rasmussen encephalitis
2008 · Elena Alvarez-Barón, Christian G. Bien, et al. · Epilepsy Research · 59
Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA)
2021 · Vicente Villanueva, Mar Carreño, et al. · Epilepsy & Behavior · 33
PDF
Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain
2023 · Vicente Villanueva, José M. Serratosa, et al. · Epilepsy & Behavior · 24
PDF
RIM3γ and RIM4γ Are Key Regulators of Neuronal Arborization
2013 · Elena Alvarez-Baron, Katrin Michel, et al. · Journal of Neuroscience · 23
PDF
Mapping analysis to predict SF-6D utilities from health outcomes in people with focal epilepsy
2022 · India Flint, Jasmina Medjedovic, et al. · The European Journal of Health Economics · 14
Value contribution of cenobamate for the treatment of Focal-Onset Seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through reflective Multi-Criteria Decision Analysis (MCDA)
2023 · Mercè Falip, Francisco Javier López González, et al. · Epilepsy & Behavior · 9
PDF
Seizures beget more than seizures: Understanding the cellular, structural, individual and societal impact of seizures in epilepsy
2025 · Matthew C. Walker, Marian Galovic, et al. · Epilepsia Open · 5
PDF
Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence
2025 · Fernando Mora, Carlos Gómez Sánchez-Lafuente, et al. · Frontiers in Psychiatry · 4
PDF
The specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults
2024 · Leslie Citrome, Elena Álvarez-Barón, et al. · International Clinical Psychopharmacology · 3
Seizure-free days as a clinical outcome measure of reduced epilepsy burden: 5-year outcomes with cenobamate treatment
2026 · José M. Serratosa, Antonio Gil-Nagel, et al. · Epilepsy & Behavior · 2
PDF
Author response for "The burden of epilepsy and unmet need in people with focal seizures"
2022 · Ioannou, Persefoni, Foster, Daniella L., et al. · Publons reviews and discussion · 2
PP261 Development Of A Mapping Algorithm To Predict SF-6D Values In People With Drug-Resistant Focal Onset Seizures
2021 · India Flint, Jasmina Medjedovic, et al. · International Journal of Technology Assessment in Health Care · 2
PDF
Perspectives on the burden of drug‐resistant epilepsy and treatment priorities: Findings from a multistakeholder survey
2026 · Simona Lattanzi, Bettina Schmitz, et al. · Epilepsia Open · 1
Management of schizophrenia patients in acute setting – a multinational survey of prescription patterns in five European countries
2025 · Miquel Bioque, Andrea Amerio, et al. · International Journal of Psychiatry in Clinical Practice · 1
PDF
163 Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures
2022 · Irene Garcia Morales, Martin J Brodie, et al. · Journal of Neurology Neurosurgery & Psychiatry · 1
Effect of Concomitant Medications on Adverse Event Frequency, Severity, and Time to Resolution in a Cenobamate Open‐Label Trial
2026 · Bernhard J. Steinhoff, Antonio Gil‐Nagel, et al. · European Journal of Neurology
Healthcare resource utilization in adults with focal onset seizures before and after initiating cenobamate: A US database analysis
2026 · Alessandro Lovera, Elena Alvarez-Baron, et al. · Epilepsy Research
AI-driven European Retrospective Database Study to predict disease onset in patients with epilepsy and depression
2026 · Alessandro Ruggieri, John Paul Leach, et al. · BMJ Neurology Open
Exploring the Impact of Schizophrenia and Its Pharmacological Treatment on Health-Related Quality of Life and Treatment Preferences
2025 · Celso Arango, Inmaculada Baeza, et al. · Patient Preference and Adherence
PDF
Long-term effect of lurasidone on cognition in patients with earlier onset schizophrenia and adults: results of pooled post-hoc analyses
2024 · I. Gabarda Inat, K. Thangavelu, et al. · Neuroscience Applied
Antidepressant effect of lurasidone in adolescent and adult patients with an acute exacerbation of schizophrenia: results of pooled post-hoc analyses
2024 · I. Gabarda Inat, K. Thangavelu, et al. · Neuroscience Applied
Effects of lurasidone on hostility in patients with an acute exacerbation of schizophrenia: a pooled analysis of short-term studies
2023 · L. Citrome, I. Gabarda Inat, et al. · Neuroscience Applied
Works count: 31
Citation count: 534
H-index: 9
I10-index: 8
Year
Topic
Type